SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule | AHK-Cu | GHK-Cu | SNAP-8 (Acetyl Octapeptide-3) |
|---|---|---|---|
| Research Topic | Tissue / Repair Research | Tissue / Repair Research | Tissue / Repair Research |
| Pharmacology | Alanine-histidine-lysine copper complex | Copper(II)-binding tripeptide complex / tissue-remodelling research | Synthetic cosmetic octapeptide; proposed SNARE-related activity, not botulinum toxin |
| PrimeCore Class | Class CExperimental / limited evidence | Class CExperimental / limited evidence | Class CExperimental / limited evidence |
| Evidence Grade | Grade EPreclinical evidence | Grade CEarly human evidence | Grade DLimited / observational evidence |
| Evidence boundary | AHK-Cu is the alanine-histidine-lysine copper complex, not GHK-Cu. A 2007 study found effects in isolated human follicles and cultured cells; the reduction in apoptotic-cell count was not statistically significant. Ex vivo human tissue is not a clinical hair-regrowth trial. | A copper-binding tripeptide with route-specific evidence; topical cosmetic research does not establish injectable systemic benefit. | SNAP-8 is associated with the cosmetic ingredient acetyl octapeptide-3, not Argireline or botulinum toxin. Limited human studies concern multi-ingredient serum and hyaluronic-acid microneedle patches, not isolated SNAP-8. The serum study enrolled 33 women and analysed 31 completers without a concurrent human control; its authors were company employees. Formulation outcomes cannot establish peptide-only efficacy, Botox equivalence or injection safety. Cosmetic notification and INCI/CosIng information do not establish injectable drug approval; exact product status remains unverified. |
| Unknowns | Insufficient data in the current dataset |
| Insufficient data in the current dataset |
| Limitations |
|
| Insufficient data in the current dataset |
| Sources |
|
| |
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions
AHK-Cu